Zacks Investment Research upgraded shares of BioSig Technologies (OTCMKTS:BSGM) from a sell rating to a buy rating in a research note released on Tuesday morning. The brokerage currently has $5.50 price objective on the stock.

According to Zacks, “BioSig Technologies, Inc. is a medical device company which is engaged in developing technology platform to improve cardiac recording during electrophysiology studies and ablation procedures. “

Separately, ValuEngine raised shares of BioSig Technologies from a hold rating to a buy rating in a research report on Thursday, August 2nd.

Shares of BSGM opened at $4.78 on Tuesday. BioSig Technologies has a 12 month low of $3.21 and a 12 month high of $7.88.

BioSig Technologies Company Profile

BioSig Technologies, Inc, a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Its product is PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures.

Further Reading: Why is insider trading harmful?

Get a free copy of the Zacks research report on BioSig Technologies (BSGM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioSig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.